Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
This is a pilot study of the safety and tolerability of photopheresis in combination with
increasing doses of oral bexarotene in patients with cutaneous T-cell lymphoma.Our hypotheses
are that the combination of bexarotene with photopheresis is safe and that bexarotene will
enhance immune response in the setting of extracorporeal photopheresis in the treatment of
cutaneous T-cell lymphoma (CTCL), resulting in a shorter time to clinical response.